Efficacy and Side Effects of Letrozole Over Clomiphene citrate for Ovulation Induction of the Patients with PCOS: A Randomized Controlled Trial

P Begum1, DR Shaha2, MK Hassan3, D Zeba4

Abstract:

Clomiphene citrate (CC) has been the drug of choice for the treatment of anovulatory subfertility in women with polycystic ovarian syndrome (PCOS) for a long time. Despite high ovulation rate of CC, its pregnancy rate is low. Letrozole, an aromatase inhibitor has been considered as an alternative of CC but its effectiveness is yet controversial. Our aim was to compare the efficacy and side effects of Letrozole over CC. This randomized control clinical trial was conducted in Diabetic Association Medical College and Hospital, Faridpur, Bangladesh from January 2018 to December 2019. A total of 160 women diagnosed as PCOS by Rotterdam criteria seeking treatment of subfertility were included in the study. Participants were randomly divided into two groups. Group A got Letrozole and Group B got CC as treatment. Transvaginal ultrasonogram (TVS) was performed on 12 to 13th day of the cycle to see the details of the follicles and the endometrium. The demographic information of the participants and the side effects of the drugs were recorded. Successful pregnancies were followed up for 12 weeks. Ovulation rate was almost similar among the participants of both of the groups. But monofo licular development and pregnancy rate were significantly higher among the Letrozole group (p = 0.004 and p = 0.008 respectively). Multifo licular development, multiple pregnancy, and abortion rate were significantly higher in the CC group. Patients who took Letrozole had significantly higher endometrial thickness than CC group. Both of the groups reported relatively similar incidence of side effects. Due to the higher pregnancy rate and lower incidence of abortion or multiple pregnancy, Letrozole can be an effective alternative to CC for the treatment of anovulatory subfertility of the PCOS patients.

Key words: Letrozole, Clomiphene citrate, Polycystic ovarian syndrome, Ovulation induction.

Introduction:

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorder of the women in reproductive age and it is the most common cause of anovulatory infertility in young adults1-4. Nearly 40% of women with subfertility are diagnosed with PCOS1,5. Subfertility in women with PCOS results from oligoovulation, diminished oocyte competence, unfavorable endometrial changes, and obesity4,6. Treating subfertility in patients with PCOS is done by ovulation induction either by medication or surgery7.

The most popular choice of medications for ovulation induction is Clomiphene citrate (CC) and Letrozole.

CC is a selective estrogen receptor modulator (SERM) and is the most common medication used for ovulation induction since its introduction in 1960 by the World Health Organization (WHO). It has been the first-line drug for treating sub-fertile women ever since8. On the plus side, CC is given orally, relatively safe, and inexpensive. But on the down-side, it causes negative changes in endometrium and cervical mucus. It may impair implantation in spite of successful induction of ovulation. Ultimately it leads to a discrepancy between ovulation and conception rate8,10. It has been observed that per cycle, CC results in a 60%-85% ovulation rate but its pregnancy rate is only 10%-20%11,12.

Letrozole is a non-steroidal aromatase inhibitor introduced for ovulation induction in 2001 by Mitwally and Casper13. It acts by decreasing the conversion of androstenedione and testosterone to estrogen in the ovary14,15. It has a short half-life and the elimination time of Letrozole is 48 hours. As a result, Letrozole has fewer adverse effects on endometrium and cervix and is usually cleared out of the system before the
implantation takes place8,16-18. Since its introduction, many clinical trials have been done to find out the effectiveness of Letrozole as ovulation induction medication. Although the outcome data vary, it has been found that Letrozole might be as effective as CC specially in women with failure or resistance to CC8,19. Besides, Letrozole has a low risk of multiple ovulation and ovarian hyperstimulation syndrome (OHSS) compared to CC20,21.

However, in 2005, Dr. Marinko Biljan reported that they had found congenital anomalies in 150 babies born from women treated with Letrozole21,22. But subsequent larger studies did not find any higher risk for congenital anomalies in the infertile group treated with Letrozole compared with CC22,23.

As the evidence for and against safety had been controversial over the last decade, randomized control trials are necessary for further understanding of the efficacy and safety margins of Letrozole and CC. In this study, we aimed at comparing the efficacy and adverse effects of these two drugs by a randomized control trial among the women seeking treatment of subfertility resulted from PCOS. Better population-based understanding of the effectiveness and adverse effects of these drugs might help the health care provider select the first-line drug for treating such patients.

Material and Methods:

This randomized controlled clinical trial was conducted at Diabetic Association Medical College and Hospital, Faridpur, Bangladesh, between January 2018 and December 2019. During this period, PCOS patients were sorted out based on the Rotterdam criteria24 among the women attended for treatment of subfertility.

Women aged <20 years and >35 years, diagnosed with secondary infertility, having abnormal serum prolactin and thyroid stimulating hormone (TSH) level, abnormal husbands’ semen analysis report, or having different medical and surgical conditions such as uterine fibroid, ovarian cyst, pelvic endometriosis, impaired hepatic or renal function, history of hypersensitivity to study drug were excluded from the study.

The study purpose and procedures were explained to all eligible women with PCOS and those who gave written informed consent were enrolled in the study. A total of 160 women who gave consent to participate in the study were allocated into two groups. Randomization was done by a computer-generated randomization plan and each enrolled subject was allocated the next available number of the randomization sequence.

Group A (Letrozole group, n =80) was given Letrozole (Letrol; Renata Limited, Bangladesh) 2.5 mg/day from day 2 to day 6 of the menstrual cycle for 3 cycles. Group B (CC group, n = 80) was given Clomiphene citrate (Ovulet; Renata Limited, Bangladesh) 100 mg/day from day 2 to day 6 of the menstrual cycle for 3 cycles.

Transvaginal ultrasound (TVS) was performed on day 12 to day 13 of the cycle. During scanning, the number and size of follicles, and the endometrial thickness were recorded. Human chorionic gonadotropin (5,000 IU) (HCG; Popular Pharmaceuticals Ltd., Bangladesh) was given intramuscularly when at least one mature follicle was ≥18 mm in diameter.

Demographic information collected included patient’s age, duration, and type of infertility, BMI, medical and surgical histories. Outcome measures were the number of mature follicles, ovulation rate, endometrial thickness, and pregnancy rate. All side effects of the drugs were recorded in a standard questionnaire during the study period. Successful pregnancies were followed up for 12 weeks.

Data were analyzed using GraphPad Prism version 8.4.0 for Mac (GraphPad Software, San Diego, California, USA). Qualitative data were described in the form of number of cases and percentages. Student's t-test and Chi-squared tests were done for analysis of numerical variables and categorical data respectively. p value <0.05 was considered statistically significant.

Prior ethical clearance was taken from the institutional review board (IRB) of Diabetic Association Medical College and Hospital.

Results:

A total of 160 PCOS patients with subfertility were included in the study. Participants were randomly divided into two groups: Group A (n=80) received letrozole (2.5 mg/day) and Group B (n=80) received CC (100 mg/day).

The demographic characteristics of the study participants are shown in Table I. There were no significant differences between participants of both groups concerning age, BMI, and duration of subfertility.

Table I: Demographic characteristics of the study group

| Variable                        | Group A (Letrozole group, n = 80) | Group B (CC group, n = 80) | p value |
|---------------------------------|-----------------------------------|-----------------------------|---------|
| Age (years)                     | 29.3 ± 3.1                        | 29.5 ± 2.1                  | 0.633   |
| BMI (kg/m²)                     | 28.4 ± 1.9                        | 28.1 ± 1.2                  | 0.234   |
| Duration of subfertility (years)| 3.3 ± 0.9                         | 3.5 ± 0.8                   | 0.139   |

Values are expressed as mean ± SD

BMI: Body mass index

| Variable                        | Group A (Letrozole group, n = 80) | Group B (CC group, n = 80) | p value |
|---------------------------------|-----------------------------------|-----------------------------|---------|
| Age (years)                     | 29.3 ± 3.1                        | 29.5 ± 2.1                  | 0.633   |
| BMI (kg/m²)                     | 28.4 ± 1.9                        | 28.1 ± 1.2                  | 0.234   |
| Duration of subfertility (years)| 3.3 ± 0.9                         | 3.5 ± 0.8                   | 0.139   |

Values are expressed as mean ± SD

BMI: Body mass index

Prior ethical clearance was taken from the institutional review board (IRB) of Diabetic Association Medical College and Hospital.

Results:

A total of 160 PCOS patients with subfertility were included in the study. Participants were randomly divided into two groups: Group A (n=80) received letrozole (2.5 mg/day) and Group B (n=80) received CC (100 mg/day).

The demographic characteristics of the study participants are shown in Table I. There were no significant differences between participants of both groups concerning age, BMI, and duration of subfertility.

Table I: Demographic characteristics of the study group

| Variable                        | Group A (Letrozole group, n = 80) | Group B (CC group, n = 80) | p value |
|---------------------------------|-----------------------------------|-----------------------------|---------|
| Age (years)                     | 29.3 ± 3.1                        | 29.5 ± 2.1                  | 0.633   |
| BMI (kg/m²)                     | 28.4 ± 1.9                        | 28.1 ± 1.2                  | 0.234   |
| Duration of subfertility (years)| 3.3 ± 0.9                         | 3.5 ± 0.8                   | 0.139   |

Values are expressed as mean ± SD

BMI: Body mass index

Prior ethical clearance was taken from the institutional review board (IRB) of Diabetic Association Medical College and Hospital.

Results:

A total of 160 PCOS patients with subfertility were included in the study. Participants were randomly divided into two groups: Group A (n=80) received letrozole (2.5 mg/day) and Group B (n=80) received CC (100 mg/day).

The demographic characteristics of the study participants are shown in Table I. There were no significant differences between participants of both groups concerning age, BMI, and duration of subfertility.

Table I: Demographic characteristics of the study group

| Variable                        | Group A (Letrozole group, n = 80) | Group B (CC group, n = 80) | p value |
|---------------------------------|-----------------------------------|-----------------------------|---------|
| Age (years)                     | 29.3 ± 3.1                        | 29.5 ± 2.1                  | 0.633   |
| BMI (kg/m²)                     | 28.4 ± 1.9                        | 28.1 ± 1.2                  | 0.234   |
| Duration of subfertility (years)| 3.3 ± 0.9                         | 3.5 ± 0.8                   | 0.139   |

Values are expressed as mean ± SD

BMI: Body mass index

Prior ethical clearance was taken from the institutional review board (IRB) of Diabetic Association Medical College and Hospital.

Results:

A total of 160 PCOS patients with subfertility were included in the study. Participants were randomly divided into two groups: Group A (n=80) received letrozole (2.5 mg/day) and Group B (n=80) received CC (100 mg/day).

The demographic characteristics of the study participants are shown in Table I. There were no significant differences between participants of both groups concerning age, BMI, and duration of subfertility.

Table I: Demographic characteristics of the study group

| Variable                        | Group A (Letrozole group, n = 80) | Group B (CC group, n = 80) | p value |
|---------------------------------|-----------------------------------|-----------------------------|---------|
| Age (years)                     | 29.3 ± 3.1                        | 29.5 ± 2.1                  | 0.633   |
| BMI (kg/m²)                     | 28.4 ± 1.9                        | 28.1 ± 1.2                  | 0.234   |
| Duration of subfertility (years)| 3.3 ± 0.9                         | 3.5 ± 0.8                   | 0.139   |

Values are expressed as mean ± SD

BMI: Body mass index

Prior ethical clearance was taken from the institutional review board (IRB) of Diabetic Association Medical College and Hospital.

Results:

A total of 160 PCOS patients with subfertility were included in the study. Participants were randomly divided into two groups: Group A (n=80) received letrozole (2.5 mg/day) and Group B (n=80) received CC (100 mg/day).

The demographic characteristics of the study participants are shown in Table I. There were no significant differences between participants of both groups concerning age, BMI, and duration of subfertility.

Table I: Demographic characteristics of the study group

| Variable                        | Group A (Letrozole group, n = 80) | Group B (CC group, n = 80) | p value |
|---------------------------------|-----------------------------------|-----------------------------|---------|
| Age (years)                     | 29.3 ± 3.1                        | 29.5 ± 2.1                  | 0.633   |
| BMI (kg/m²)                     | 28.4 ± 1.9                        | 28.1 ± 1.2                  | 0.234   |
| Duration of subfertility (years)| 3.3 ± 0.9                         | 3.5 ± 0.8                   | 0.139   |

Values are expressed as mean ± SD

BMI: Body mass index

Prior ethical clearance was taken from the institutional review board (IRB) of Diabetic Association Medical College and Hospital.
Discussion:

Polycystic ovarian syndrome is one of the main endocrine causes of subfertility\(^4\,25\). Clomiphene citrate has been the first line treatment for treating anovulatory subfertility since 1960s\(^9\,26\). Due to several changes in the endometrium caused by CC and CC resistance, low rate of pregnancy occurs in spite of higher rates of ovulation\(^13\,27\,28\). Letrozole, a third-generation aromatase inhibitor has been introduced as a good alternative but its efficacy and side effects are still controversial.

In our study, we have randomly divided 160 patients diagnosed with PCOS seeking for treatment of subfertility in 2 groups. One group got CC and another group got Letrozole as treatment for ovulation induction. Demographically, there were no significant differences between the participants of both groups.

We performed TVS on day 12 to 13 of the cycle and we didn't find any significant difference in ovulation rate among the Letrozole and CC group \((p = 0.627)\). In a review in 2013, Kar had also found that there was no statistical difference of ovulation rate per cycle between women taking Letrozole or CC\(^22\).

Successful pregnancies were followed up till twelve weeks. During this period, abortion rate was significantly higher in CC group \((p = <0.001)\). None of our patients in either of the group had ectopic pregnancy or OHSS. However, 13.7% of patients in Letrozole group and 18.7% of patients in CC group complaint of gastrointestinal symptoms such as nausea, vomiting, abdominal distension, abdominal pain, constipation, flatulence, and stomach discomfort. Among the other side effects, both of the groups had an almost equal incidence of hot flashes, fatigue and generalized malaise, dysmenorrhea or cramps, and breast tenderness or pain. Table III shows the unwanted outcomes in both groups.

**Table II: Outcome of ovarian stimulation**

| Variable                          | Group A (Letrozole group, \(n = 80\)) | Group B (CC group, \(n = 80\)) | \(p\) value |
|-----------------------------------|--------------------------------------|--------------------------------|-------------|
| Ovulation rate                    | 50/80 (62.5%)                        | 47/80 (58.8%)                  | 0.627       |
| Monofollicular development        | 53/80 (66.3%)                        | 35/80 (43.7%)                  | 0.004       |
| Multifollicular development       | 26/80 (32.5%)                        | 45/80 (56.2%)                  | 0.002       |
| Endometrial thickness (mean ± SD) | 9.3 ± 0.4                            | 6.2 ± 0.2                      | <0.001      |
| Pregnancy rate                    | 37/80 (46.3%)                        | 21/80 (26.3%)                  | 0.008       |
| Multiple pregnancy rate           | 1/37 (2.7%)                          | 5/21 (23.8%)                   | 0.011       |

Values are expressed as \(n/n\) (%)

**Table III: Unwanted outcomes**

| Variable                           | Group A (Letrozole group, \(n = 80\)) | Group B (CC group, \(n = 80\)) | \(p\) value |
|------------------------------------|--------------------------------------|--------------------------------|-------------|
| Abortion rate (till the end of 12\(^{th}\) week) | 1/37 (2.7%)                          | 4/21 (19.0%)                  | 0.033       |
| Ectopic pregnancy                  | 0/37 (0%)                            | 0/21 (0%)                     | NA          |
| OHSS                               | 0/80 (0%)                            | 0/80 (0%)                     | NA          |
| Gastrointestinal side effects      | 11/80 (13.7%)                        | 15/80 (18.7%)                 | 0.391       |
| Hot flashes                        | 3/80 (3.7%)                          | 4/80 (5.0%)                   | 0.699       |
| Fatigue                            | 5/80 (6.2%)                          | 6/80 (7.5%)                   | 0.754       |
| Dysmenorrhea or cramps             | 10/80 (12.5%)                        | 8/80 (10.0%)                  | 0.616       |
| Breast tenderness or pain          | 9/80 (11.2%)                         | 12/80 (15.0%)                 | 0.322       |

Values are expressed as \(n/n\) (%)

OHSS: Ovarian hyperstimulation syndrome
Efficacy and Side effects of Letrozole over Clomiphene citrate for Ovulation Induction of the Patients with PCOS: A Randomized Controlled Trial

However, we found that the thickness of the endometrium was significantly higher in Letrozole group than CC group ($p = <0.001$). In a study by Bayar et al. have found that some of the participants of CC group had endometrial thickness <5 mm but none of the participants in Letrozole group had endometrial thickness <5 mm$^{29}$. Mitwally and Casper have also found significantly higher endometrial thickness in women treated with Letrozole compared with women treated with CC$^{15}$.

Although the ovulation rate among both groups had no significant difference, pregnancy rate was significantly higher in Letrozole group ($p = 0.008$). In several other similar studies done by Ibrahim et al, Legro et al and others have also found that pregnancy rate was significantly higher among the women in Letrozole group$^{10,30,31}$.

We have found that multifollicular development and incidence of multiple pregnancy was significantly higher in the CC group. Badawy et al and others have also found higher multifollicular development in CC group compared to Letrozole group$^{10,30,32}$.

As we followed up the pregnancy until twelve weeks, we have found that abortion rate was significantly higher in the CC group. In a study done by Ibrahim et al. followed up pregnancy till eight weeks and similarly, they have found that abortion rate was higher among the women who took CC$^{30}$. However, in a study done by Legro et al found no significant difference in pregnancy loss between these two groups$^{31}$.

In our study, women in the CC group had more gastrointestinal symptoms compared to the women in the Letrozole group. At the same time, the incidence of hot flushes, fatigue, breast tenderness, or pain was higher among the women in the CC group, but the incidence of dysmenorrhea or cramps was higher among the Letrozole group. But none of the side effects was statistically significant difference among the two groups. None of the women in either of the groups developed ovarian hyperstimulation syndrome or had an ectopic pregnancy in our study.

A study done by Legro et al among 750 women had found that CC had a higher incidence of hot flushes whereas Letrozole had a higher incidence of fatigue and dizziness. Other adverse effects were almost similar in two groups$^{15}$.

Comparing both groups, Letrozole showed promising effectiveness as fertility treatment and a potent alternative to CC for the treatment of anovulatory subfertility. Further study with larger numbers of participants might help clarify the efficacy and safety of Letrozole over CC.

Conclusion:

Letrozole can be an effective alternative to CC for the treatment of anovulatory infertility. Letrozole offers a higher pregnancy rate and a greater likelihood of singleton pregnancy. It can be the choice of drug for the treatment of subfertility in women with polycystic ovary syndrome.

Conflict of interest: None

References:

1. Barthelmess EK, Naz RK. Polycystic ovary syndrome: Current status and future perspective. Frontiers in Bioscience (Elite edition). 2014; 6:104-19.
2. Adams J, Dwpolson D, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed).1986; 293(6543):355-9.
3. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. The Lancet. 2007; 370(9588):685-97.
4. Trikudanathan S. Polycystic ovarian syndrome. Medical Clinics. 2015; 99(1):221-35.
5. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998; 138(3):269-74.
6. Wood JR, Dumesic DA, Abbott DH, Strauss III JF. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. The Journal of Clinical Endocrinology & Metabolism. 2007; 92(2):705-13.
7. Nahid L, Sirous K. Comparison of the effects of letrozole and clomiphene citrate for ovulation induction in infertile women with polycystic ovary syndrome. Minerva ginecologica. 2012; 64(3):253-8.
8. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2014(2).
9. Casper RF, Mitwally MF. Aromatase inhibitors for ovulation induction. The Journal of Clinical Endocrinology & Metabolism. 2006; 91(3):760-71.
10. Al-Fozan H, Al-Khadouri M, Tan SL, Tuluani T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertility and sterility. 2004; 82(6):1561-3.
11. Fisher SA, Reid RL, Van Vugt DA, Casper RF. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertility and sterility. 2002; 78(2):280-5.
12. Guzick DS. Ovulation induction management of PCOS. Clinical obstetrics and gynecology. 2007; 50(1):255-67.
13. Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertility and sterility. 2001; 75(2):305-9.
14. Aletebi F, Alaa N. The effect of letrozole versus clomiphene citrate on ovulation induction in polycystic ovarian syndrome patients: RCT. Journal of Evidence-Based Women's Health Journal Society. 2013; 3(2):51-3.

15. Cole PA, Robinson CH. Mechanism and Inhibition of Cytochrome P-450 Aromatase. Journal of Medicinal Chemistry. 1990; 33(11):2933-42.

16. Baruah J, Roy KK, Rahman SM, Kumar S, Sharma JB, Karmakar D. Endometrial effects of letrozole and clomiphene citrate in women with polycystic ovary syndrome using spiral artery Doppler. Archives of gynecology and obstetrics. 2009; 279(3):311-4.

17. Jirge PR, Patil RS. Comparison of endocrine and ultrasound profiles during ovulation induction with clomiphene citrate and letrozole in ovulatory volunteer women. Fertility and andsterility. 2010; 93(1):174-83.

18. Samani FG, Farzadi I, Nezami N, Tarzamni MK, Soleimani F. Endometrial and follicular development following letrozole intervention in unexplained infertile patients failed to get pregnant with clomiphene citrate. Archives of gynecology and obstetrics. 2009; 280(2):201-5.

19. Badawy A, Abdel Aal I, Abulatta M. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertility and andsterility. 2009; 92(3):849-52.

20. Lee VC, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Clinical endocrinology. 2011; 74(5):537-46.

21. Biljan MM, Hemmings R, Brassard N. The Outcome of 150 Babies Following the Treatment With Letrozole or Letrozole and Gonadotropins. Fertility and andsterility. 2005; 84:S95.

22. Kar S. Current evidence supporting "letrozole" for ovulation induction. Journal of human reproductive sciences. 2013; 6(2):93.

23. Casper RF, Mitwally MF. A historical perspective of aromatase inhibitors for ovulation induction. Fertility and sterility. 2012; 98(6):1352-5.

24. Rotterdam ESHRE/ASRM? Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction. 2004; 19(1):41-7.

25. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database of Systematic Reviews. 2016(12).

26. Kistnner RW. Induction of ovulation with clomiphene citrate (Clomid). Obstetrical and Gynecological Survey. 1965; 20(6):873-900.

27. Gonen Y, Casper RF. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth. Human Reproduction. 1990; 5(6):670-4.

28. Dehbozhe S, parsanezhd ME, Alborzi S, Zarei A. Effect of clomiphene citrate on endometrium thickness and echogenic patterns. International Journal of Gynecology & Obstetrics. 2003; 80(1):49-53.

29. Bayar Ü, Tanriverdi HA, Barut A, Ayoğlu F, Özcan O, Kaya E. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertility and sterility. 2006; 85(4):1045-8.

30. Ibrahim MI, Moustafa RA, Abdel-Azeem AA. Letrozole versus clomiphene citrate for superovulation in Egyptian women with unexplained infertility: a randomized controlled trial. Archives of gynecology and obstetrics. 2012; 286(6):1581-7.